‘Dangling’ Accelerated Approval Reviews Expand At US FDA
Executive Summary
The oncologic drugs advisory committee’s upcoming reviews are moving beyond the PD-1/PDL-1 inhibitor class – and to a very different type of sponsor.
You may also be interested in...
239 Days: Oncopeptides' Myeloma Drug Pepaxto Comes Off Market Just Months After Accelerated Approval
Withdrawal announcement marks shortest interval ever from accelerated approval to market removal after OCEAN confirmatory trial showed an adverse overall survival trend and US FDA said a hypothesis-generating subgroup analysis would need to be borne out in another study.
Medicaid Spending On Accelerated Approvals ‘Outsized’ Relative To Use
A new study highlights a subset of high-cost drugs in Medicaid for which legal and policy tools may be available to manage spending growth.
Pazdur To Oncology Drug Developers: Step Back, Slow Down – And Find The Right Dose
FDA’s “Project Optimus” draft guidance on dose optimization is in the works. Until then, randomized dosing studies need to be an IND-level conversation.